Cargando…

Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma

Treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has greatly improved clinical outcomes in patients with diffuse large B-cell lymphoma (DLBCL) compared with CHOP. The mechanism of rituximab-induced cell death is poorly understood. We found that rituxi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Tiansuo, Ren, He, Wang, Xiuchao, Liu, Pengfei, Yan, Fan, Jiang, Wenna, Li, Yang, Li, Jing, Gribben, John G., Jia, Li, Hao, Jihui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695028/ https://www.ncbi.nlm.nih.gov/pubmed/26315113

Ejemplares similares

Blockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma
por: Zhang, Tian, et al.
Publicado: (2019)

IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer
por: Zhao, Tiansuo, et al.
Publicado: (2020)

Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab
por: Hu, Yunfei, et al.
Publicado: (2014)

Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes
por: Wang, Xiuchao, et al.
Publicado: (2016)

Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma
por: Zhao, Tiansuo, et al.
Publicado: (2014)

Correction: Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma
por: Zhao, Tiansuo, et al.
Publicado: (2019)

Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma
por: Hu, Xin, et al.
Publicado: (2017)

Primary breast diffuse large B-cell lymphoma in the era of rituximab
por: Zhang, Na, et al.
Publicado: (2016)

Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure
por: Hu, Shaoxuan, et al.
Publicado: (2018)

Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
por: Yelvington, Bradley J.
Publicado: (2018)

Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis
por: Zhou, Xuan, et al.
Publicado: (2017)

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
por: Vacirca, Jeffrey L., et al.
Publicado: (2013)

The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era
por: Kobayashi, T, et al.
Publicado: (2016)

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma
por: Habbous, Steven, et al.
Publicado: (2020)

Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
por: Papageorgiou, Sotirios G., et al.
Publicado: (2022)

Hypoxia-Inducible Factor-1α Regulates Chemotactic Migration of Pancreatic Ductal Adenocarcinoma Cells through Directly Transactivating the CX3CR1 Gene
por: Zhao, Tiansuo, et al.
Publicado: (2012)

CypA, a Gene Downstream of HIF-1α, Promotes the Development of PDAC
por: Zhang, Huan, et al.
Publicado: (2014)

Rituximab Treatment Strategy for Patients with Diffuse Large B-Cell Lymphoma after First-Line Therapy: A Systematic Review and Meta-Analysis
por: Ren, Yuan-Rong, et al.
Publicado: (2015)

Reverse effect of Semaphorin-3F on rituximab resistance in diffuse large B-cell lymphoma via the Hippo pathway
por: Li, Qiong, et al.
Publicado: (2023)

Population pharmacokinetics of rituximab in patients with diffuse large B‐cell lymphoma and association with clinical outcome
por: Rozman, Samo, et al.
Publicado: (2017)

A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma
por: Ko Ko, Nway Le, et al.
Publicado: (2020)

Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era
por: Gutierrez, Antonio, et al.
Publicado: (2020)

The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma
por: Palmieri, R., et al.
Publicado: (2019)

Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
por: Murayama, Kayoko, et al.
Publicado: (2022)

Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications
por: Papageorgiou, Sotirios G., et al.
Publicado: (2021)

The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B‐cell lymphoma
por: Kawasaki, Natsumi, et al.
Publicado: (2022)

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance
por: Liu, Yizhen, et al.
Publicado: (2020)

P1224: EFFICACY OF RITUXIMAB AND BIOSIMILAR RITUXIMAB IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA, A DANISH POPULATION BASED ANALYSIS
por: Haujir, A., et al.
Publicado: (2022)

An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era
por: Sun, Feifei, et al.
Publicado: (2018)

Rituximab-Based Therapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: Individualized Risk-Adapted Therapy Approach Using Molecular Subtypes
por: Fan, Lei, et al.
Publicado: (2017)

STAT3-coordinated migration facilitates the dissemination of diffuse large B-cell lymphomas
por: Pan, Yi-Ru, et al.
Publicado: (2018)

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
por: Shi, Yuankai, et al.
Publicado: (2020)

Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma
por: Liu, Jing, et al.
Publicado: (2019)

IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era
por: Chen, Xiangli, et al.
Publicado: (2020)

Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
por: Guan, Xu-Wen, et al.
Publicado: (2020)

STAT-3 RNAscope Determination in Human Diffuse Large B-Cell Lymphoma()
por: Tamma, Roberto, et al.
Publicado: (2019)

Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease
por: Mondello, Patrizia, et al.
Publicado: (2014)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021)

Identifying and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing
por: Jeon, Youngwoo
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u4042aq4u177rftju8eqmc9185